Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors

Cancer

Volumn 123, Issue 16, 2017, Pages 3080-3087

  Moore, Kathleen N ^a   Borghaei, Hossein ^b   O'Malley, David M ^c   Jeong, Woondong ^d   Seward, Shelly M ^e   Bauer, Todd M ^f   Perez, Raymond P ^g   Matulonis, Ursula A ^h   Running, Kelli L ⁱ   Zhang, Xiaoyan ⁱ   Ponte, Jose F ⁱ   Ruiz Soto, Rodrigo ⁱ   Birrer, Michael J ^j  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d San Antonio Cancer Institute   (United States)

^e WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f SARAH CANNON RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF KANSAS   (United States)

^h DANA FARBER CANCER INSTITUTE   (United States)

ⁱ IMMUNOGEN INC   (United States)

^j MASSACHUSETTS GENERAL HOSPITAL   (United States)

more..

Author keywords

antibody drug conjugate; clinical trial; folate receptor; phase 1; targeted therapy

Indexed keywords

MIRVETUXIMAB SORAVTANSINE; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; MAYTANSINE; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BLURRED VISION; CLINICAL ARTICLE; COHORT ANALYSIS; CORNEA OPACITY; DIARRHEA; DISEASE COURSE; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG TOLERANCE; ENDOMETRIUM CANCER; FATIGUE; FEMALE; HUMAN; HYPOPHOSPHATEMIA; KIDNEY CARCINOMA; LUNG EDEMA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NON SMALL CELL LUNG CANCER; OVARY CANCER; PERIPHERAL NEUROPATHY; PHARMACOKINETIC PARAMETERS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PUNCTATE KERATITIS; SOLID MALIGNANT NEOPLASM; ANALOGS AND DERIVATIVES; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, RENAL CELL; CHEMICALLY INDUCED; CLINICAL TRIAL; DOSE RESPONSE; ENDOMETRIAL NEOPLASMS; KERATITIS; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PATHOLOGY; VERY ELDERLY; VISUAL DISORDER;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, RENAL CELL; DIARRHEA; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOMETRIAL NEOPLASMS; FATIGUE; FEMALE; HUMANS; HYPOPHOSPHATEMIA; IMMUNOCONJUGATES; KERATITIS; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MAYTANSINE; MIDDLE AGED; NEOPLASMS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; VISION DISORDERS;

EID: 85018295090     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.30736     Document Type: Article

References (33)

1. Frei E 3rd, Elias A, Wheeler C, Richardson P, Hryniuk W. The relationship between high-dose treatment and combination chemotherapy: the concept of summation dose intensity. Clin Cancer Res. 1998;4:2027-2037.
2. Chari RV. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res. 2008;41:98-107.
3. Yewale C, Baradia D, Vhora I, Misra A. Proteins: emerging carrier for delivery of cancer therapeutics. Expert Opin Drug Deliv. 2013;10:1429-1448.
4. Mukherjee B, Karmakar SD, Hossain CM, Bhattacharya S. Peptides, proteins and peptide/protein-polymer conjugates as drug delivery system. Protein Pept Lett. 2014;21:1121-1128.
5. Chari RV, Miller ML, Widdison WC. Antibody-drug conjugates: an emerging concept in cancer therapy. Angewandte Chemie. 2014;53:3796-3827.
6. Chudasama V, Maruani A, Caddick S. Recent advances in the construction of antibody-drug conjugates. Nat Chem. 2016;8:114-119.
7. Elnakat H, Ratnam M. Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev. 2004;56:1067-1084.
8. Salazar MD, Ratnam M. The folate receptor: what does it promise in tissue-targeted therapeutics? Cancer Metastasis Rev. 2007;26:141-152.
9. Assaraf YG, Leamon CP, Reddy JA. The folate receptor as a rational therapeutic target for personalized cancer treatment. Drug Resist Updat. 2014;17:89-95.
10. Ledermann JA, Canevari S, Thigpen T. Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments. Ann Oncol. 2015;26:2034-2043.
11. Lutz RJ. Targeting the folate receptor for the treatment of ovarian cancer. Transl Cancer Res. 2015;4:118-126.
12. Dosio F, Milla P, Cattel L. EC-145, a folate-targeted Vinca alkaloid conjugate for the potential treatment of folate receptor-expressing cancers. Curr Opin Investig Drugs. 2010;11:1424-1433.
13. Ambrosio AJ, Suzin D, Palmer EL, Penson RT. Vintafolide (EC145) for the treatment of folate-receptor-alpha positive platinum-resistant ovarian cancer. Expert Rev Clin Pharmacol. 2014;7:443-450.
14. Spannuth WA, Sood AK, Coleman RL. Farletuzumab in epithelial ovarian carcinoma. Expert Opin Biol Ther. 2010;10:431-437.
15. Vergote I, Armstrong D, Scambia G, et al. A randomized, double-blind, placebo-controlled, phase III study to assess efficacy and safety of weekly farletuzumab in combination with carboplatin and taxane in patients with ovarian cancer in first platinum-sensitive relapse. J Clin Oncol. 2016;34:2271-2278.
16. Endocye Inc. Merck and Endocyte Announce Independent DSMB Recommends Vintafolide PROCEED Phase 3 Trial Be Stopped for Futility Following Interim Analysis. Endocyte Inc. Available at: http://investor.endocyte.com/releasedetail.cfm?ReleaseID=844838. Accessed October 25, 2016.
17. Lambert JM. Drug-conjugated antibodies for the treatment of cancer. Br J Clin Pharmacol. 2013;76:248-262.
18. Erickson HK, Widdison WC, Mayo MF, et al. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Bioconjug Chem. 2010;21:84-92.
19. Hong EE, Erickson H, Lutz RJ, et al. Design of coltuximab ravtansine, a CD19-targeting antibody-drug conjugate (ADC) for the treatment of B-Cell malignancies: structure-activity relationships and preclinical evaluation. Mol Pharm. 2015;12:1703-1716.
20. Ab O, Whiteman KR, Bartle LM, et al. IMGN853, a folate receptor-alpha (FRalpha)-targeting antibody-drug conjugate, exhibits potent targeted antitumor activity against FRalpha-expressing tumors. Mol Cancer Ther. 2015;14:1605-1613.
21. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247.
22. Moore KN, Ponte J, Lorusso PM, et al. Relationship of pharmacokinetics (PK), toxicity, and initial evidence of clinical activity with IMGN853, a folate receptor alpha (FRa) targeting antibody drug conjugate in patients (Pts) with epithelial ovarian cancer (EOC) and other FRa-positive solid tumors [abstract]. J Clin Oncol. 2014;32:15S. Abstract 5571.
23. Konner JA, Bell-McGuinn KM, Sabbatini P, et al. Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin Cancer Res. 2010;16:5288-5295.
24. Sasaki Y, Miwa K, Yamashita K, et al. A phase I study of farletuzumab, a humanized anti-folate receptor alpha monoclonal antibody, in patients with solid tumors. Invest New Drugs. 2015;33:332-340.
25. Gomez-Roca CA, Boni V, Moreno V, et al. A phase I study of SAR566658, an anti CA6-antibody drug conjugate (ADC), in patients (Pts) with CA6-positive advanced solid tumors (STs) (NCT01156870) [abstract]. J Clin Oncol. 2016;34:15S Abstract 2511.
26. Eaton JS, Miller PE, Mannis MJ, Murphy CJ. Ocular adverse events associated with antibody-drug conjugates in human clinical trials. J Ocul Pharmacol Ther. 2015;31:589-604.
27. Parslow AC, Parakh S, Lee F, Gan HK, Scott AM. Antibody-drug conjugates for cancer therapy. Biomedicines. 2016;4:14.
28. Polakis P. Antibody drug conjugates for cancer therapy. Pharmacol Rev. 2016;68:3-19.
29. Marchetti C, Palaia I, Giorgini M, et al. Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review. Onco Targets Ther. 2014;7:1223-1236.
30. Vergote IB, Marth C, Coleman RL. Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications. Cancer Metastasis Rev. 2015;34:41-52.
31. Kalli KR, Oberg AL, Keeney GL, et al. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol. 2008;108:619-626.
32. Toffoli G, Russo A, Gallo A, et al. Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer. Int J Cancer. 1998;79:121-126.
33. Moore KN, Martin LP, O'Malley DM, et al. Safety and activity of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a phase I expansion study. J Clin Oncol. 2017;35:1112-1118.